AMD Invests in Absci to Accelerate AI-Driven Drug Discovery

AMD Invests in Absci to Accelerate AI-Driven Drug Discovery
Generative AI drug creation company Absci Corporation announced on Wednesday a strategic collaboration with AMD to enhance its AI-driven drug discovery capabilities. Through this partnership, Absci will deploy AMD’s Instinct accelerators and ROCm software to power critical AI drug discovery workloads, including de novo antibody design models. As part of the partnership, AMD is making a USD 20 million investment in Absci via a private investment in public equity (PIPE), highlighting the “growing demand for AI in drug discovery,” Absci said.

Also Read

  • Make Telecom Talk My Trusted Source
  • Source of Google
  • Source of Google

Also Read: Accenture Invests in 1910 Genetics to Accelerate AI-Driven Drug Discovery

AMD Investment Boosts Absci’s AI Drug Discovery

“The strategic partnership supports Absci’s mission of creating better biologics for patients, faster by providing optimized AI solutions for complex biological modeling that offer exceptional performance, reduced infrastructure costs, and faster innovation cycles,” the AI drug creation company said on January 8, 2025. The company noted that this partnership is expected to further expand biopharma adoption of AMD Instinct accelerators and ROCm software.

“This partnership with AMD gives us the unique advantage of working closely with a partner that is deeply committed to supporting our needs while providing the most efficient, innovative AI solutions available,” said Sean McClain, Founder and CEO of Absci. “AMD high-performance compute will enable us to further the development of next-generation antibody therapeutics, and we are excited about the potential that this partnership holds to accelerate the future of drug discovery.”